Preparing for the third decade of biosimilars-Reference-Cited by-同舟云学术

Preparing for the third decade of biosimilars

Published:2023-08-03 Issue:8 Volume:23 Page:651-652
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Abraham Ivo¹^ORCID

Affiliation:

1. Guest Editor; Center for Health Outcomes and PharmacoEconomic Research, R. Ken Coit College of Pharmacy, University of Arizona, Tucson, AZ, USA

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2023.2247916

Reference12 articles.

1. Center for Biosimilars. Biosimilar approvals. 2023 Jul 17. [cited 2023 Aug 10]. Available from: https://www.centerforbiosimilars.com/biosimilar-approvals.

2. Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries

3. Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: simulation study

4. Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan

5. Center for Biosimilars. [cited 2023 Aug 10]. Available from: https://www.centerforbiosimilars.com/search?searchTerm=Ivo+Abraham+column.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. On-body injector pegfilgrastim for chemotherapy-induced neutropenia prophylaxis: Current Status;Cancer Treatment and Research Communications;2024

3. Response of a new rumen-derived Bacillus licheniformis to different carbon sources;Frontiers in Microbiology;2023-11-01